HIV合并HBV感染的患者抗病毒治疗效果分析

发布时间：2018-01-06 08:13

本文关键词：HIV合并HBV感染的患者抗病毒治疗效果分析　出处：《中国艾滋病性病》2016年10期 　论文类型：期刊论文

【摘要】：目的评价替诺福韦(TDF)+拉米夫定(3TC)+依菲韦伦(EFV)或TDF+3TC+克力芝(LPV/r)治疗方案,对艾滋病病毒(HIV)合并感染乙型肝炎病毒(HBV)患者的治疗效果,对合并感染者死亡因素进行分析,为临床抗病毒治疗提供参考。方法对46例HIV/HBV合并感染患者实施TDF+3TC+EFV或TDF+3TC+LPV/r方案治疗,治疗3、6、12个月后随访,分析CD4+T淋巴细胞、HIV RNA、HBV DNA、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)等指标的变化。结果 46例HIV/HBV合并感染患者治疗3、6、12个月后,CD4+T淋巴细胞数分别增加了76个/μL、138个/μL和145个/μL;治疗6、12个月后,HIV-RNA抑制率分别为79.49%和95.56%,HBV-DNA抑制率分别为77.14%和97.06%;抗病毒治疗12个月内AST、ALT先升后降,治疗6个月时,除2例肝功能异常外,其余肝功均复常;HIV/HBV合并感染者病死率为10.87%。结论 TDF+3TC+EFV或TDF+3TC+LPV/r方案对HIV和HBV均有很强的抑制作用,是一种高效、安全的治疗HIV/HBV合并感染的首选方案。
[Abstract]:Objective evaluation for Nuo Fuwei (TDF) and lamivudine (3TC) + Yvette efavirenz (EFV) or TDF+3TC+ (LPV/r) kriton Shiba treatment of AIDS virus (HIV) infection in patients with hepatitis B virus (HBV) patients, with infection of death factors, to provide reference for clinical treatment. Methods 46 cases of HIV/HBV infection in patients with TDF+3TC+EFV or TDF+3TC+LPV/r regimen treatment were followed up for 3,6,12 months after the analysis of CD4+T HIV RNA, HBV lymphocyte, DNA, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and other indicators of change. The results of 46 cases of HIV/HBV with treatment 3,6,12 months after infection with CD4+T. The number of lymphocytes increased by 76 / L, 138 / L and 145 / L; 6,12 months after treatment, the inhibition rate of HIV-RNA were 79.49% and 95.56%, HBV-DNA inhibition rates were 77.14% and 97.06%; antiviral therapy within 12 months of AST, ALT first and then decreased, treatment for 6 months, except for 2 cases of abnormal liver function, the liver function were often complex; the mortality was inhibited 10.87%. conclusion TDF+3TC+EFV or TDF+3TC+LPV/r scheme is very strong on both HIV and HBV HIV/HBV infection is a high effective and safe in the treatment of HIV/HBV infection and the preferred solution.

【作者单位】：郑州市第六人民医院;河南省艾滋病防治协会;中国生物技术股份有限公司;
【分类号】：R512.91;;R512.6+2
【正文快照】： 我国艾滋病病毒(Human immune deficiency vi-rus,HIV)感染者中,乙型肝炎病毒表面抗原(HB-sAg)阳性率在11.2%~17.7%之间[1-3],合并乙型肝炎病毒(Hepatitis B virus,HBV)感染很普遍,HIV/HBV合并感染使艾滋病病人联合抗病毒治疗更为复杂。HIV主要损害人体的免疫系统,从而加速HBV

【相似文献】